← Back
Data updated: Jun 28, 2026
SCOTT-GROSS COMPANY
Pharma Pharmaceuticals
SCOTT-GROSS COMPANY is a pharmaceutical company with 1 FDA-approved products.
2013
Since
1
Drugs
-
Trials
2
New Drugs (2yr)
Modality:
1 Small Molecules
SCOTT-GROSS COMPANY's Key Drugs
SCOTT-GROSS COMPANY's core commercial portfolio centers on MEDICAL AIR, USP — its most strategically important drugs approved in the last 15 years.
SCOTT-GROSS COMPANY's Recent FDA Approvals
SCOTT-GROSS COMPANY secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
SCOTT-GROSS COMPANY's Therapeutic Areas
Disease areas where SCOTT-GROSS COMPANY has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
SCOTT-GROSS COMPANY Pipeline Snapshot
Active clinical trials for SCOTT-GROSS COMPANY across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • MEDICAL AIR, USP leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2013-07-14
- Latest
- 2013-07-14
- Applications
- 1